Surra, caused by Trypanosoma evansi, is a major constraint to camel health and productivity in arid and semi-arid regions. Despite Kazakhstan’s large camel population, peer-reviewed data on surra epidemiology remain scarce.

A cross-sectional seroepidemiological survey was conducted in two camel-breeding regions of Kazakhstan (Mangystau and Kyzylorda) during 2024 and 2025. Serum samples (n = 2,745 in 2024; n = 2,900 in 2025) were tested for anti-T. evansi antibodies using the complement fixation test (CFT) and the formol gel test (FGT). Seroprevalence was expressed with 95% confidence intervals (CI), and regional/temporal differences were assessed using Pearson’s chi-square test.

In Mangystau, CFT prevalence decreased from 5.0% (95% CI: 2.15–11.18) in 2024 to 0.78% (95% CI: 0.21–2.82) in 2025 (p = 0.0319), while FGT positivity declined from 65.0% to 5.88% (p < 0.001). Conversely, in Kyzylorda, CFT prevalence increased significantly from 4.0% (95% CI: 3.32–4.82) to 8.88% (95% CI: 7.87–10.01; p < 0.001), whereas FGT values rose slightly from 7.8% to 8.96% without statistical significance (p = 0.1504).

This study provides the first multi-year evidence of T. evansi circulation in camels in Kazakhstan, revealing contrasting regional dynamics: a sharp decline in Mangystau and a significant increase in Kyzylorda. These findings underscore the heterogeneous nature of surra epidemiology and highlight the need for continued surveillance and combined diagnostic approaches to inform control strategies.

This study assessed the replication of the Nigeria 75/1 strain of the peste des petits ruminants (PPR) virus in Vero cells cultured in suspension using microcarriers. This approach represents a modern platform that combines the advantages of suspension cultivation with the high specific productivity of cells achieved through adhesion to the surface of microcarriers.

The influence of various parameters—type of microcarriers (Cytodex 1 and Cytodex 3), seeding concentration of Vero cells, infectious dose of the virus, and cultivation duration—on the system’s productivity was investigated. Experimental results demonstrated that the use of microcarriers ensures reliable adhesion and active proliferation of Vero cells, thereby creating optimal conditions for virus replication. The obtained viral titer (≥ 6.75 log TCID₅₀/cm³) exceeded the values reported for traditional monolayer cultivation, indicating increased efficiency of virus replication.  Thus, the obtained data confirm the high potential of cultivation technology using microcarriers both for experimental studies and for industrial development and production of a vaccine against PPR.

Ticks are carriers of numerous pathogens, and their bacterial composition, abundance, diversity, and interaction affect both their growth and the efficiency of disease transmission. The emergence of next-generation metagenomic sequencing (NGS) technologies has expanded the possibilities for detecting and characterising microbial pathogens. Sequence data analysis can identify the presence of Brucella DNA in ticks and determine its genetic characteristics. In the spring of 2023, tick samples were collected in the Taskalinsky district of the West Kazakhstan Region. Sequencing of the 16S rRNA genes of bacteria in tick samples was performed using the Ion Torrent platform based on NGS technology. 

In D. marginatus_WKR_Taskala tick samples, metagenomic analysis identified Brucella suis bv. 3 (25%) and other Brucella species (75%). Analysis of the reads obtained as a result of metagenomic sequencing of the tick sample identified 3,973 reads, of which 2,966 were classified as Brucella spp. and 1,007 as Brucella suis bv. 3. The alpha diversity indices for the D. marginatus_WKR_Taskala sample were: Shannon = 0.797, Simpson 1−D = 0.473, Margalef = 0.241. Ticks are recognised as the main carriers of a wide range of diseases among domestic and wild animals compared to other arthropods. Despite numerous studies on the link between brucellosis transmission and ticks, the exact role of ticks in the transmission of this disease and the associated risks remain unclear.

Surra, caused by Trypanosoma evansi, is a major constraint to camel health and productivity in arid and semi-arid regions. Despite Kazakhstan’s large camel population, peer-reviewed data on surra epidemiology remain scarce.

A cross-sectional seroepidemiological survey was conducted in two camel-breeding regions of Kazakhstan (Mangystau and Kyzylorda) during 2024 and 2025. Serum samples (n = 2,745 in 2024; n = 2,900 in 2025) were tested for anti-T. evansi antibodies using the complement fixation test (CFT) and the formol gel test (FGT). Seroprevalence was expressed with 95% confidence intervals (CI), and regional/temporal differences were assessed using Pearson’s chi-square test.

In Mangystau, CFT prevalence decreased from 5.0% (95% CI: 2.15–11.18) in 2024 to 0.78% (95% CI: 0.21–2.82) in 2025 (p = 0.0319), while FGT positivity declined from 65.0% to 5.88% (p < 0.001). Conversely, in Kyzylorda, CFT prevalence increased significantly from 4.0% (95% CI: 3.32–4.82) to 8.88% (95% CI: 7.87–10.01; p < 0.001), whereas FGT values rose slightly from 7.8% to 8.96% without statistical significance (p = 0.1504).

This study provides one of the first systematic multi-year assessments of T. evansi circulation in camels in Kazakhstan, revealing contrasting regional dynamics, with a sharp decline in Mangystau and a significant increase in Kyzylorda. These findings underscore the heterogeneous nature of surra epidemiology and highlight the need for continued surveillance and combined diagnostic approaches to inform control strategies. 

A pharmaceutical development of an ointment based on a thick extract of Filipendula vulgaris  M. obtained by ultrasonic extraction has been carried out. The use of ultrasonic treatment made it possible to increase the efficiency of extracting biologically active substances, reduce extraction time, and preserve thermolabile components of the plant material.

The chemical composition of the thick extract was studied using gas chromatography–mass spectrometry (GC/MS). The analysis revealed the presence of a complex of phenolic compounds, flavonoids, organic acids, esters, and other secondary metabolites with pronounced antioxidant and antiinflammatory activity. The obtained data confirm the pharmacological significance of the extract and the feasibility of its use as an active ingredient in the development of soft dosage forms.

Based on the studied extract, five model compositions of the ointment were developed, differing in the ratio of base components and the concentration of the active substance. Each model was evaluated for physicochemical, organoleptic, and rheological characteristics. Parameters such as consistency, resistance to delamination, pH, viscosity, and uniformity of extract distribution in the ointment mass were determined. According to the totality of the obtained data, the optimal composition was identified, providing structural stability and pharmaco-technological properties that meet the requirements for soft dosage forms.

Toxicological studies and pharmacological tests of the developed samples were carried out. No signs of acute toxicity or irritating effects were observed during topical application. Experimental evaluation of anti-inflammatory activity demonstrated a significant reduction of inflammatory reactions, indicating a pronounced therapeutic potential of the developed ointment.

Thus, the study results confirm that the thick extract of Filipendula vulgaris  M. is a promising herbal source of biologically active substances for the development of soft dosage forms with antiinflammatory properties. The developed ointment composition is characterized by stability, safety, and pharmacological efficacy, making it a potential basis for further preclinical and technological studies aimed at pharmaceutical implementation.

Oncological diseases are one of the most pressing problems of mankind. Unfortunately, modern methods of cancer prevention and treatment have not kept pace with the trend of increasing mortality and the emergence of new cases of these diseases. One of the reasons for this is the lack of preclinical in vitro models that would accurately simulate human tumors, their diverse morphology, molecular characteristics and microenvironment. Studies of tumors, their morphological characteristics, treatment prognosis, and therapeutic approaches are still carried out on two-dimensional models of cell and animal cultures. However, two-dimensional cell culture models have limitations due to the lack of tissue-specific architecture, biochemical signals, and interactions between cells and the surrounding matrix, so they cannot accurately display and simulate complex processes in vivo. In turn, using animals to model tumor diseases and test drugs for them is not only expensive and time-consuming, but also these models cannot simulate biological reactions of humans due to species differences. Three-dimensional tissue models are more suitable in terms of morphology, migration, proliferation, response to drug treatment, as well as gene and protein expression, and more accurately mimic tissue growth in vivo. This review presents current scientific data on the use of cellular biotechnologies to study carcinogenesis and their potential in precision medicine.

This paper presents the results of a study on the selection of a stabilizing medium for the human respiratory syncytial virus (RSV). Studies were conducted using various stabilizing media used in biotechnology, examining their effects on the storability of the studied virus during storage under different temperature and time conditions, followed by determination of the residual biological activity of virus samples in a continuous Vero cell culture.

The study found that all virus samples containing peptone, sucrose, gelatin, and their mixtures at low temperatures (minus 40 °C and plus 4 °C) had a beneficial effect on virus storability, whereas high temperatures (plus 37 °C and 22 °C) reduced the biological activity of the RSV. These data are important for the storage, transportation, and use of the virus in the development of diagnostic and vaccine preparations against this infection.